Mereo BioPharma Signs License Deal with Sentynl for Rare Lung Disease Treatment

Key Facts

In a move reflecting the growing trend of strategic partnerships in the biotech sector to advance rare disease treatments, Mereo BioPharma has entered into an option and license agreement with Sentynl Therapeutics. The deal grants Sentynl the U.S. commercial rights for alvelestat, a potential treatment for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. According to reports, this partnership aims to leverage Sentynl's commercial infrastructure to lead the U.S. market entry for this lead asset.

Under the agreement terms, Mereo is eligible to receive up to $40 million in upfront and R&D payments through the filing of a New Drug Application (NDA). Furthermore, the company stands to receive double-digit royalties on sales upon the exercise of the option. This arrangement provides Mereo with non-dilutive funding to support its ongoing development efforts, while Sentynl, a subsidiary of Zydus Lifesciences, expands its specialized rare disease portfolio.

Looking ahead, Mereo plans to collaborate with Sentynl during the option period to refine the design of the global Phase 3 study for alvelestat. As of August 11, 2026, specific price data for MREO was unavailable in the market database, necessitating a focus on qualitative catalysts. With no major upcoming sector-specific events in the economic calendar, investors will likely monitor the timeline for the option exercise and further clinical progress.